Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

2.

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

3.

Stevia leaf extract has potential as anticancer treatment, researchers find

4.

Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation

5.

Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot